Sernova Corp. Responds to Market Activity
 | |||||||||
 |  |  |  | ||||||
LONDON, ONTARIO – TheNewswire - December 11, 2020 – At the request of IIROC (“Investment Industry Regulatory Organization of Canada”), Sernova Corp. (“Sernova” or the “Company”) (TSX-V:SVA) (OTCQB:SEOVF) (FSE:PSH) wishes to confirm that the Company’s management is unaware of any material or undisclosed information or change in the Company’s operations that would account for the recent increase in price and market activity.
ABOUT SERNOVA CORP.
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e. human donor cells, corrected human cells, and stem cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com
For further information contact:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126